
    
      This is a treatment protocol designed only to provide access to everolimus (RAD) for
      maintenance immunosuppression. The objectives are to facilitate the management of patients on
      maintenance immunosuppression therapy who are completing everolimus trials,

        -  To provide everolimus maintenance therapy through this access program and

        -  To collect and review safety data for up to 120 months or until the project has been
           discontinued whichever comes first.

        -  To collect and review safety data for up to 120 months or when Certican is commercially
           available in the given indication and reimbursed by appropriate payors or the project
           has been discontinued whichever comes first.
    
  